Clinical trials: Adrenal Tumors
Pheochromocytoma, Metastatic, Ultrasonography
Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of…
- Conditions
- Pheochromocytoma, Metastatic, Ultrasonography, Paraganglioma, Malignant, Pheochromocytoma Malignant
- Trial name
- NCT06015061
- Testing
- Contrast-enhanced ultrasound(CEUS)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Adrenocortical Carcinoma
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug…
- Trial name
- GALACCTIC (NCT00924989)
- Testing
- OSI-906
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 139 people
- Sponsor
- Astellas Pharma Inc
Adrenal Insufficiency, Leukemia, Lymphoblastic, Acute, Pediatric
A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children
Plain Language Summary: Background Glucocorticoids are stress hormones produced by the human body to control inflammation and regulate the immune system. Cortisol is the most well-known example of a glucocorticoid.
- Conditions
- Adrenal Insufficiency, Leukemia, Lymphoblastic, Acute, Pediatric, Lymphoma, Lymphoblastic
- Trial name
- LeukemiaCort (NCT06861530)
- Where
- 2 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University Children's Hospital Basel
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Outcome Assessment, Adrenal Neoplasm
Textbook Outcome in Adrenal Neoplasms
BACKGROUND: Textbook outcome (TO) is a multidimensional quality management tool that uses a set of traditional surgical measures to reflect an "ideal" surgical result for a particular pathology.
- Trial name
- NCT05888753
- Testing
- Adrenalectomy
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Hospital General Universitario de Alicante
Gastric Neoplasm, Early Gastric Cancer
RCT of Gastric ESD With or Without Epineprhine Added Solution
This is an international multi-center randomised controlled study comparing outcomes of gastric endoscopic submucosal dissection (ESD) with or without addition of epinephrine in the submucosal injection solution.
- Trial name
- NCT04032119
- Testing
- Endoscopic submucosal dissection, Epinephrine
- Where
- 7 sites in Hong Kong, Japan and 2 more
- Volunteers
- 800 people
- Sponsor
- Chinese University of Hong Kong
Hyperandrogenemia, Obesity
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Trial name
- NCT01422707
- Testing
- Hydrocortisone
- Where
- United States
- Sponsor
- University of Virginia
Cancer, Adrenal
Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)
The adrenal cancer research network "COMETE" is federating French research on rare adrenal cancers. COMETE achieved major breakthroughs in the molecular characterization of adrenocortical carcinomas (ACC) and malignant…
- Trial name
- COMETE-CARE (NCT05754892)
- Testing
- Blood sample, Urine sample, Tumor sample
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pituitary Adenoma
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation.
- Trial name
- NCT02574793
- Testing
- continuous glucose monitoring
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Colorectal Neoplasms
Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer
This study investigates the effect of acupuncture in reducing symptom distress in adults with advanced colon cancer.
- Trial name
- NCT00034034
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Osteogenesis Imperfecta, Osteoporosis
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia
- Trial name
- NCT07412782
- Testing
- REMS
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Meyer Children's Hospital IRCCS
Adrenal Incidentaloma, Adrenocortical Carcinoma
Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical…
- Trial name
- SERENDIPITY (NCT02324647)
- Where
- Netherlands
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Head and Neck Cancer
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002659
- Testing
- cisplatin-e therapeutic implant
- Where
- 28 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Matrix Pharmaceutical
Adrenal Cortex Neoplasms, Adrenal Cortex Diseases
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
In adrenal tumors, the investigators will examine if there is any correlation between WIESS criteria, prognosis of the tumor, and the different labeling index of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53…
- Trial name
- NCT02747355
- Volunteers
- 70 people
- Sponsor
- Bnai Zion Medical Center
Adrenocortical Carcinoma
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Trial name
- NCT04318730
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- West China Hospital
Adrenocortical Carcinoma
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01528956
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT03008369
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Aldosterone-Producing Adenoma
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA).
- Trial name
- NCT05839483
- Testing
- CXCR4
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has genetic changes called GNAQ or GNA11 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439357
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi